EGFR and lung cancer: For instance, the T790M acquired mutations in Epidermal Growth Factor Receptor (EGFR) were associated with resistance to the tyrosine kinase inhibitors inhibitor (afatinib, erlotinib and gefitinib) in lung cancer [24].